Improved agreement means NICE now recommends lung cancer treatment

Osimertinib recommended at two different places in the treatment pathway for locally advanced or metastatic epidermal growth factor receptor (EGFR)-positive NSCLC.

Please sign in or register for FREE

No comments yet.